- Home
- INMB vs GUTS Comparison
INMB vs GUTS Comparison
Compare INMB & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- GUTS
- Stock Information
- Founded
- INMB 2015
- GUTS 2010
- Country
- INMB United States
- GUTS United States
- Employees
- INMB N/A
- GUTS N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- GUTS
- Sector
- INMB Health Care
- GUTS
- Exchange
- INMB Nasdaq
- GUTS NYSE
- Market Cap
- INMB 109.9M
- GUTS 98.7M
- IPO Year
- INMB 2019
- GUTS 2024
- Fundamental
- Price
- INMB $4.58
- GUTS $2.02
- Analyst Decision
- INMB Strong Buy
- GUTS Buy
- Analyst Count
- INMB 2
- GUTS 2
- Target Price
- INMB $21.00
- GUTS $18.00
- AVG Volume (30 Days)
- INMB 261.5K
- GUTS 480.3K
- Earning Date
- INMB 10-31-2024
- GUTS 11-12-2024
- Dividend Yield
- INMB N/A
- GUTS N/A
- EPS Growth
- INMB N/A
- GUTS N/A
- EPS
- INMB N/A
- GUTS N/A
- Revenue
- INMB $42,000.00
- GUTS $97,000.00
- Revenue This Year
- INMB N/A
- GUTS N/A
- Revenue Next Year
- INMB N/A
- GUTS N/A
- P/E Ratio
- INMB N/A
- GUTS N/A
- Revenue Growth
- INMB N/A
- GUTS N/A
- 52 Week Low
- INMB $4.47
- GUTS $1.74
- 52 Week High
- INMB $14.74
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- INMB 32.26
- GUTS 40.33
- Support Level
- INMB $4.45
- GUTS $2.02
- Resistance Level
- INMB $6.26
- GUTS $2.24
- Average True Range (ATR)
- INMB 0.30
- GUTS 0.23
- MACD
- INMB -0.18
- GUTS -0.05
- Stochastic Oscillator
- INMB 5.84
- GUTS 17.29
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.